Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Hypertension 3Diabetes Mellitus, Type 2 3Cushing Syndrome 3ACTH Syndrome, Ectopic 3Pituitary ACTH Hypersecretion 2Pancreatic Neoplasms 2Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Adrenocortical Carcinoma 1Adrenal Cortex Neoplasms 1

Interventions

Mitotane 4Cisplatin 3pembrolizumab 2cixutumumab 2Etoposide 2Doxorubicin 2Dichlorodiphenyldichloroethane 2sodium thiosulfate 1relacorilant 1pegfilgrastim 1milademetan 1gossypol acetic acid 1cabozantinib 1avelumab 1antineoplaston AS 2-1 1antineoplaston A10 1Sunitinib 1Streptozocin 1Platinum 1Nivolumab 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Fentanyl 1Ethane 1Cytoreduction Surgical Procedures 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Adrenocortical Carcinoma × relacorilant × Clear all
NCT02804750 2019-10-15

Study to Evaluate CORT125134 in Participants With Cushing's Syndrome

Corcept Therapeutics

Phase 2 Completed
35 enrolled 13 charts
Endocrine

ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Cushing Syndrome, Diabetes Mellitus, Type 2, Hypertension, Adrenocortical Carcinoma, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡